Study identifier:D2287R00186
ClinicalTrials.gov identifier:NCT06419413
EudraCT identifier:N/A
CTIS identifier:N/A
A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and endotypes associated with Differential Outcomes that may Support Future Development of Personalized Treatment Strategies in Chinese Population
asthma
N/A
Yes
-
All
1000
Observational
18 Years - 75 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Cohort A up to 100 healthy participants, | - |
Cohort B up to 200 mild asthmatics on as-needed low dose inhaled corticosteroids (ICS)-formoterol, or low dose ICS plus as-needed short-acting β2 agonists (SABA), without the need for other controller medication | - |
Cohort C up to 300 moderate to severe asthmatics on low or medium dose ICS-long acting β2 agonists (LABA), high dose ICS alone or in combination with LABA with pre-bronchodilator FEV1 <80% predictedu | - |
Cohort D up to 200 asthmatics with protocol defined asthma exacerbation. | - |